$RFL News Article - Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613 (devimistat) for Patients with Relapsed or Refractory Burkitt's Lymphoma/Leukemia to Massachusetts General Hospital in Boston
https://marketwirenews.com/news-releases/rafa...89706.html